|drug3837||collection of swabs Wiki||1.00|
|drug3891||fingertip tests for POC assays Wiki||1.00|
|drug3811||blood draw Wiki||0.71|
There is one clinical trial.
The study is to investigate the antibody response in the blood and saliva of people with a known COVID-19 infection in the canton of Baselland.
Description: Qualitative method validation: qualitative result of the ELISA (Patient does / does not have immunity) as the gold standard compared to the POC using univariate measures to derive sensitivity and specificity of the POC.Measure: Qualitative method validation (yes/ no) Time: at baseline
Description: Quantitative method validation: antibody concentration from the ELISA are related to the dichotomous result from POC.Measure: Quantitative method validation (antibody concentrations) Time: at baseline
Description: Antibody and T cell repertoires and transcriptional profiles of cells will be used to identify potential antibody and T cell clones correlated with COVID-19 protection.Measure: Immune cell repertoire sequencing Time: at baseline
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports